Latest Articles
Elise Mak
·
Yesterday
Leap Therapeutics' anti-DKK1 antibody in combination with BeiGene's anti-PD-1 antibody demonstrated clinical activity in both first- and second-line advanced gastric or gastroesophageal junction cancer patients. More news from Eluminex Bio, CTTQ, Neurophth, BeiGene and the CDE.
News
Elise Mak
·
2 days ago
Innovent Biologics is licensing the Greater China rights to up to three enzyme-specific inhibitors from Amagma Therapeutics to strengthen its inflammatory disease portfolio. More news from Pharbers, BioTroy, Biocytogen, Neukio and Hengrui Pharma.
News
Elise Mak
·
3 days ago
Mabwell is the 13th pre-revenue biotech startup listed on STAR. It raised RMB3.477 billion ($547 million) with an offer price of RMB34.8 apiece. It opened at RMB32 then further dropped to RMB24.5 to end the day.
News
Danni Yin
·
3 days ago
The NMPA’s run of speedy approvals continued in the last month of 2021 as Chinese regulators granted the first marketing approvals to 16 new drugs and accepted NDAs for 11 more new ones.
China NMPA Approval Tracker
Elise Mak
·
4 days ago
Abbisko Therapeutics has inked a pact with Eli Lilly to develop and commercialise novel molecules against an undisclosed target for cardiometabolic diseases. More news from ReviR Therapeutics, Leman and SparX Bio.
News
Elise Mak
·
5 days ago
CStone's study provides the only anti-PD-L1 immunotherapy plus chemotherapy option for squamous NSCLC patients worldwide. More news from Junsai, Gracell, BeyondSpring, HISUN, EastChina, Shenogen and Betta.
News
Shi Yingzi
·
5 days ago
Several big series A financing in December warrant attention, as they speak of a wider trend for drug innovation in China. Big pharmaceutical companies are sharing risks, and scientists are creating a mRNA platform.
China Biotech Fundraising Tracker
Elise Mak
·
8 days ago
After securing COVID-19 vaccines from Providence Therapeutics, Everest Medicines now gets hold of oral drugs for the coronavirus to shore up its COVID portfolio. More news from REC Bio.
News
Danni Yin
·
8 days ago
Early-stage assets made up half of the licensing deals in 2021, up 10% from the previous year.
China Deals Tracker
Elise Mak
·
9 days ago
Chinese biotech startups Belief Biomed is one of the few gene therapy players with in-house manufacturing capabilities, and Regor is able to deliver one preclinical candidate in 10 months with its rCARD platform.
Feature